Toward effective prescription of inhaled corticosteroids in chronic airway disease

References

• MurrayCJLLopezADMeasuring the global burden of diseaseN Engl J Med2013369544845723902484
   PubMed Web of Science ®Google Scholar
• BatemanEDHurdSSBarnesPJGlobal strategy for asthma management and prevention: GINA executive summaryEur Respir J200831114317818166595
   PubMed Web of Science ®Google Scholar
• 2018 GINA Report, Global Strategy for Asthma Management and Prevention Available from: http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/Accessed April 24, 2018
   Google Scholar
• VogelmeierCFCrinerGJMartinezFJChronic obstructive pulmonary diseaseEur Respir J2017121433438
   Google Scholar
• SorianoJBAbajobirAAAbateKHGlobal, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015Lancet Respir Med20175969170628822787
   PubMed Web of Science ®Google Scholar
• KeatingsVMBarnesPJGranulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjectsAm J Respir Crit Care Med199715524494539032177
   PubMed Web of Science ®Google Scholar
• HaldarPPavordIDShawDECluster analysis and clinical asthma phenotypesAm J Respir Crit Care Med2008178321822418480428
   PubMed Web of Science ®Google Scholar
• BrusselleGPriceDGruffydd-JonesKThe inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UKInt J Chron Obstruct Pulmon Dis2015102207221726527869
   PubMed Web of Science ®Google Scholar
• SterkPJChronic diseases like asthma and COPD: do they truly exist?Eur Respir J201647235936126828042
   PubMed Web of Science ®Google Scholar
• GOLD COPD Strategy2014 Available from: www.GOLDCOPD.orgAccessed April 24, 2018
   Google Scholar
• PereraWRHurstJRWilkinsonTMAInflammatory changes, recovery and recurrence at COPD exacerbationEur Respir J200729352753417107990
   PubMed Web of Science ®Google Scholar
• WedzichaJAAntibiotics at COPD exacerbations: the debate continuesThorax2008631194094218984809
   PubMed Web of Science ®Google Scholar
• WillsonJBatemanEDPavordILloydAKrivasiTEsserDCost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonistsAppl Health Econ Health Policy201412444745924974107
   PubMedGoogle Scholar
• MagnussenHTetzlaffKCalverleyPMAInhaled glucocorticoids and COPD exacerbationsN Engl J Med201537219394
   Google Scholar
• PriceDBRussellRMaresRMetabolic effects associated with ICS in patients with COPD and comorbid type 2 diabetes: a historical matched cohort studyPLoS One2016119e016290327658209
   PubMed Web of Science ®Google Scholar
• PavordIDBeasleyRAgustiAAfter asthma: redefining airways diseasesLancet20183911011835040028911920
   PubMed Web of Science ®Google Scholar
• AgustiABelEThomasMTreatable traits: toward precision medicine of chronic airway diseasesEur Respir J201647241041926828055
   PubMed Web of Science ®Google Scholar
• AgustiABafadhelMBeasleyRPrecision medicine in airway diseases: moving to clinical practiceEur Respir J2017504pii: 1701655
   Web of Science ®Google Scholar
• BafadhelMGreeningNJHarvey-DunstonTSevere hospitalised exacerbations of COPD with an eosinophilic phenotype have favourable outcomes with prednisolone therapy sub-analysis from a prospective multi-centre randomised control trialThorax201368Suppl IIIA16
   Google Scholar
• BafadhelMMcKennaSTerrySAcute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkersAm J Respir Crit Care Med2011184666267121680942
   PubMed Web of Science ®Google Scholar
• PavordIDLettisSLocantoreNBlood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPDThorax201671211812526585525
   PubMed Web of Science ®Google Scholar
• GOLD 2018 Global Strategy for the Diagnosis, Management and Prevention of COPD Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/Accessed April 24, 2018
   Google Scholar
• GelfandMLAdministration of cortisone by the aerosol method in the treatment of bronchial asthmaN Engl J Med1951245829329414863574
   PubMed Web of Science ®Google Scholar
• MoonJCFlettASGodmanBBGrossoAMWierzbickiASGetting better value from the NHS drug budgetBMJ2010341c644921169320
   PubMed Web of Science ®Google Scholar
• BatemanEDBousheyHABousquetJCan guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL studyAm J Respir Crit Care Med2004170883684415256389
   PubMed Web of Science ®Google Scholar
• RabeKFVermeirePASorianoJBMaierWCClinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) studyEur Respir J200016580280711153575
   PubMed Web of Science ®Google Scholar
• SurukiRYDaughertyJBBoudiafNAlbersFCThe frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USABMC Pulm Med20171717428449686
   PubMed Web of Science ®Google Scholar
• PriceDWestDBrusselleGManagement of COPD in the UK primary-care setting: an analysis of real-life prescribing patternsInt J Chron Obstruct Pulmon Dis2014988990425210450
   PubMed Web of Science ®Google Scholar
• LevyMLThomasMSmallIPearceLPinnockHStephensonPSummary of the 2008 BTS/SIGN British Guideline on the management of asthmaPrim Care Respir J200918Suppl 1S1S1619209371
   PubMedGoogle Scholar
• FordPARussellREBarnesPJICS and COPD: time to clear the airInt J Chron Obstruct Pulmon Dis2009428929019684862
   PubMedGoogle Scholar
• BurgePSCalverleyPMJonesPWSpencerSAndersonJAMaslenTKRandomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trialBMJ200032072451297130310807619
   PubMed Web of Science ®Google Scholar
• WhitePThorntonHPinnockHGeorgopoulouSBoothHPOver-treatment of COPD with inhaled corticosteroids –iImplications for safety and costs: cross-sectional observational studyPLoS One2013810e7522124194824
   PubMed Web of Science ®Google Scholar
• SuissaSKezouhAErnstPInhaled corticosteroids and the risks of diabetes onset and progressionAm J Med2010123111001100620870201
   PubMed Web of Science ®Google Scholar
• SuissaSBarnesPJInhaled corticosteroids in COPD: the case againstEur Respir J2009341131619567599
   PubMed Web of Science ®Google Scholar
• PriceDBRussellRMaresRMetabolic effects associated with ICS in patients with COPD and comorbid type 2 diabetes: a historical matched cohort studyPLoS One2016119e016290327658209
   PubMed Web of Science ®Google Scholar
• DiamantZBootJDMantzouranisEFlohrRSterkPJGerth van WijkRBiomarkers in asthma and allergic rhinitisPulm Pharmacol Ther201023646848120601050
   PubMed Web of Science ®Google Scholar
• ParulekarADDiamantZHananiaNARole of T2 inflammation biomarkers in severe asthmaCurr Opin Pulm Med2016221596826574724
   PubMed Web of Science ®Google Scholar
• MartinMJWilsonEGerrard-TarpeyWThe utility of exhaled nitric oxide in patients with suspected asthmaThorax201671656256426903595
   PubMed Web of Science ®Google Scholar
• BafadhelMPavordIDRussellREKEosinophils in COPD: just another biomarker?Lancet Respir Med20175974775928601554
   PubMed Web of Science ®Google Scholar
• BurgelP-RPaillasseurJ-LPeeneBTwo distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortalityPLoS One2012712e5104823236428
   PubMed Web of Science ®Google Scholar
• MooreWCMeyersDAWenzelSEIdentification of asthma phenotypes using cluster analysis in the Severe Asthma Research ProgramAm J Respir Crit Care Med2010181431532319892860
   PubMed Web of Science ®Google Scholar
• Sendin-HernandezMPAvila-ZarzaCSanzCIdentification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysisAm J Respir Crit Care Med20177216372
   Google Scholar
• WeatherallMTraversJShirtcliffePMDistinct clinical phenotypes of airways disease defined by cluster analysisEur Respir J200934481281819357143
   PubMed Web of Science ®Google Scholar
• GreenRHBrightlingCEMcKennaSAsthma exacerbations and sputum eosinophil counts: a randomised controlled trialLancet200236093471715172112480423
   PubMed Web of Science ®Google Scholar
• WoodruffPGModrekBChoyDFT-helper type 2-driven inflammation defines major subphenotypes of asthmaAm J Respir Crit Care Med2009180538839519483109
   PubMed Web of Science ®Google Scholar
• BarnesNCSharmaRLettisSCalverleyPMABlood eosinophils as a marker of response to inhaled corticosteroids in COPDEur Respir J20164751374138226917606
   PubMed Web of Science ®Google Scholar
• Di MarcoFSotgiuGSantusPLong-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysisRespir Res20181911829368604
   PubMed Web of Science ®Google Scholar
• BuhlRGessnerCSchuermannWEfficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority studyThorax201570431131925677679
   PubMed Web of Science ®Google Scholar
• BeehK-MWestermanJKirstenA-MThe 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary diseasePulm Pharmacol Ther201532535925956072
   PubMed Web of Science ®Google Scholar
• WedzichaJABanerjiDChapmanKRIndacaterol-glycopyrronium versus salmeterol-fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• RocheNChapmanKRVogelmeierCFBlood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. data from the FLAME trialAm J Respir Crit Care Med201719591189119728278391
   PubMed Web of Science ®Google Scholar
• MagnussenHWatzHKirstenAStepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationaleRespir Med2014108459359924477080
   PubMed Web of Science ®Google Scholar
• MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
   PubMed Web of Science ®Google Scholar
• SuissaSRossiAWeaning from inhaled corticosteroids in COPD: the evidenceEur Respir J20154651232123526521271
   PubMed Web of Science ®Google Scholar
• RossiAvan der MolenTdel OlmoRINSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPDEur Respir J20144461548155625359348
   PubMed Web of Science ®Google Scholar
• WoutersEFMPostmaDSFokkensBWithdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trialThorax200560648048715923248
   PubMed Web of Science ®Google Scholar
• van der ValkPMonninkhofEvan der PalenJZielhuisGvan HerwaardenCEffect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE studyAm J Respir Crit Care Med2002166101358136312406823
   PubMed Web of Science ®Google Scholar
• WatzHTetzlaffKWoutersEFMBlood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trialLancet Respir Med20164539039827066739
   PubMed Web of Science ®Google Scholar
• PavordIDLettisSAnzuetoABarnesNBlood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysisLancet Respir Med20164973174127460163
   PubMed Web of Science ®Google Scholar